FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3021935068> ?p ?o ?g. }

• W3021935068 endingPage "e119" @default.
• W3021935068 startingPage "e117" @default.
• W3021935068 abstract "To the Editor We read with great interest Ranucci et al’s1 review on the “trials and tribulations” of fibrinogen level determination that was recently published in Anesthesia & Analgesia. This topic has become even more important with the rise of the coronavirus pandemic since severe hyperfibrinogenemia is a characteristic finding in patients critically ill with coronavirus disease 2019 (COVID-19) respiratory failure.2 We wanted to take this opportunity to bring another limitation of the Clauss method of fibrinogen determination to readers’ attention, as it can have important implications for care of these patients. Given the hypercoagulability seen in COVID-19 patients, anticoagulation with low-molecular-weight heparin has been recommended by the International Society of Thrombosis and Hemostasis.3 However, since antithrombin levels can be significantly lower than normal in this patient population,2 heparin’s effectiveness may be limited in some cases. Our institution has been selectively using direct thrombin inhibitors (DTIs) to overcome this problem. Unbeknownst to clinicians, this affected our laboratory’s method for measuring fibrinogen levels, causing them to be vastly underestimated. An example of the magnitude in underestimation is provided in the Figure for illustrative purposes.Figure.: The graph demonstrates an example of the magnitude of which an argatroban infusion can have upon the measurement of fibrinogen levels determined by the Clauss assay. The patient’s initially reported levels (blue line) on the day argatroban was started (which were repeated for confirmation) were almost an order of magnitude lower from previous measurements taken while on a heparin infusion. These samples were diluted as described in the text to decrease the effects of the argatroban and rerun, producing a “corrected” fibrinogen level (orange line).The Clauss method of fibrinogen measurement is similar to a thrombin time. Platelet poor plasma is exposed to a reagent containing supraphysiologic concentrations of thrombin and clot formation is sensed by mechanical or photo-optical means. The time to clot detection is compared against reference plasma to generate a corresponding fibrinogen level. The concentration of thrombin in the Clauss reagent varies by manufacturer and what instrumentation is being used. When present in the patient sample, DTIs inhibit the thrombin in the Clauss reagent, prolonging the time to clot formation, and thus underestimating the fibrinogen concentration. Reagents with lower thrombin concentrations are more susceptible to DTI inference. This problem has been reported on several different commercial platforms with samples containing both bivalirudin and argatroban.4,5 The Clauss assay in our particular laboratory uses a reagent with the highest commercially available thrombin concentration—100 NIH units (UNIH)/mL (QFA Thrombin, Instrumentation Laboratories, Bedford, MA). Despite this high level, “inhibitors” can still interfere with fibrinogen assessment. This can be assessed by performing a dilution procedure. This involves taking the patient plasma sample and performing a 1:1 dilution with HemosIL Factor Diluent (Instrumentation Laboratories), a nonactive buffer solution. This reduces the effect of the DTI. The Figure provides an example of how large a difference this can make on the measurement of fibrinogen levels. Viscoelastic testing represents an alternative to the Clauss method for following fibrinogen levels in the setting of DTIs. The platelet–fibrinogen interactions assessed by maximum amplitude on thromboelastography (TEG) (Haemonetics, Boston, MA) or maximum clot formation on rotational thromboelastometry (ROTEM) (Instrumentation Laboratories) are relatively unaffected by the presence of DTIs.6 In the example provided in the Figure, a ROTEM was obtained following the reported severe drop in fibrinogen on day 4 and resulted in the following notable parameters: EXTEM clotting time of 477 seconds (normal range 43–82 seconds) and FIBTEM maximum clot firmness of 39 mm (normal range 7–24 mm). The clotting time was appropriately prolonged, indicating thrombin inhibition by the argatroban, while the increased maximum clot firmness was still able to reflect the hyperfibrinogenemia that was present. This discordance between the ROTEM findings and the reported fibrinogen level by the Clauss method prompted the initial investigations into diluting the DTI samples. The hypercoagulability caused by COVID-19 is still not well understood. Fibrinogen levels are an important piece of the puzzle, not only from a research aspect but for patient care. However, it is important for both scientists and clinicians to understand that their measurement is not always entirely straightforward. Cheryl L. Maier, MD, PhDDepartment of Pathology and Laboratory MedicineEmory University School of MedicineAtlanta, Georgia Nicholas A. Barker, PharmDDepartment of PharmacyEmory St Joseph’s HospitalAtlanta, Georgia Roman M. Sniecinski, MD, MScDepartment of AnesthesiologyEmory University School of MedicineAtlanta, Georgia[email protected]" @default.
• W3021935068 created "2020-05-13" @default.
• W3021935068 creator A5008083283 @default.
• W3021935068 creator A5021756706 @default.
• W3021935068 creator A5087100932 @default.
• W3021935068 date "2020-05-04" @default.
• W3021935068 modified "2023-09-28" @default.
• W3021935068 title "Falsely Low Fibrinogen Levels in COVID-19 Patients on Direct Thrombin Inhibitors" @default.
• W3021935068 cites W2089647014 @default.
• W3021935068 cites W2740213883 @default.
• W3021935068 cites W2796046218 @default.
• W3021935068 cites W2984316350 @default.
• W3021935068 cites W3008461878 @default.
• W3021935068 cites W3012860481 @default.
• W3021935068 doi "https://doi.org/10.1213/ane.0000000000004949" @default.
• W3021935068 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7219828" @default.
• W3021935068 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32371744" @default.
• W3021935068 hasPublicationYear "2020" @default.
• W3021935068 type Work @default.
• W3021935068 sameAs 3021935068 @default.
• W3021935068 citedByCount "9" @default.
• W3021935068 countsByYear W30219350682020 @default.
• W3021935068 countsByYear W30219350682021 @default.
• W3021935068 countsByYear W30219350682022 @default.
• W3021935068 countsByYear W30219350682023 @default.
• W3021935068 crossrefType "journal-article" @default.
• W3021935068 hasAuthorship W3021935068A5008083283 @default.
• W3021935068 hasAuthorship W3021935068A5021756706 @default.
• W3021935068 hasAuthorship W3021935068A5087100932 @default.
• W3021935068 hasBestOaLocation W30219350681 @default.
• W3021935068 hasConcept C126322002 @default.
• W3021935068 hasConcept C164705383 @default.
• W3021935068 hasConcept C177713679 @default.
• W3021935068 hasConcept C2777292125 @default.
• W3021935068 hasConcept C2777557582 @default.
• W3021935068 hasConcept C2779026020 @default.
• W3021935068 hasConcept C2779036427 @default.
• W3021935068 hasConcept C2779612170 @default.
• W3021935068 hasConcept C2780868729 @default.
• W3021935068 hasConcept C2908647359 @default.
• W3021935068 hasConcept C42219234 @default.
• W3021935068 hasConcept C57002609 @default.
• W3021935068 hasConcept C71924100 @default.
• W3021935068 hasConcept C89560881 @default.
• W3021935068 hasConcept C99454951 @default.
• W3021935068 hasConceptScore W3021935068C126322002 @default.
• W3021935068 hasConceptScore W3021935068C164705383 @default.
• W3021935068 hasConceptScore W3021935068C177713679 @default.
• W3021935068 hasConceptScore W3021935068C2777292125 @default.
• W3021935068 hasConceptScore W3021935068C2777557582 @default.
• W3021935068 hasConceptScore W3021935068C2779026020 @default.
• W3021935068 hasConceptScore W3021935068C2779036427 @default.
• W3021935068 hasConceptScore W3021935068C2779612170 @default.
• W3021935068 hasConceptScore W3021935068C2780868729 @default.
• W3021935068 hasConceptScore W3021935068C2908647359 @default.
• W3021935068 hasConceptScore W3021935068C42219234 @default.
• W3021935068 hasConceptScore W3021935068C57002609 @default.
• W3021935068 hasConceptScore W3021935068C71924100 @default.
• W3021935068 hasConceptScore W3021935068C89560881 @default.
• W3021935068 hasConceptScore W3021935068C99454951 @default.
• W3021935068 hasIssue "2" @default.
• W3021935068 hasLocation W30219350681 @default.
• W3021935068 hasLocation W30219350682 @default.
• W3021935068 hasLocation W30219350683 @default.
• W3021935068 hasLocation W30219350684 @default.
• W3021935068 hasLocation W30219350685 @default.
• W3021935068 hasOpenAccess W3021935068 @default.
• W3021935068 hasPrimaryLocation W30219350681 @default.
• W3021935068 hasRelatedWork W1864503139 @default.
• W3021935068 hasRelatedWork W1973879662 @default.
• W3021935068 hasRelatedWork W1986000434 @default.
• W3021935068 hasRelatedWork W2052292793 @default.
• W3021935068 hasRelatedWork W2055893076 @default.
• W3021935068 hasRelatedWork W2065122181 @default.
• W3021935068 hasRelatedWork W2334573148 @default.
• W3021935068 hasRelatedWork W2416372787 @default.
• W3021935068 hasRelatedWork W2419833267 @default.
• W3021935068 hasRelatedWork W55507748 @default.
• W3021935068 hasVolume "131" @default.
• W3021935068 isParatext "false" @default.
• W3021935068 isRetracted "false" @default.
• W3021935068 magId "3021935068" @default.
• W3021935068 workType "article" @default.